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Purpose: Cholesterol lowering statins have been demonstrated to exert anti-tumoral effects on breast cancer by
decreasing proliferation as measured by Ki67. The biological mechanisms behind the anti-proliferative effects remain
elusive. The aim of this study was to investigate potential statin-induced effects on the central cell cycle regulators
cyclin D1 and p27.
Experimental design: This phase II window-of-opportunity trial (Trial registration: ClinicalTrials.gov NCT00816244,
NIH) included 50 patients with primary invasive breast cancer. High-dose atorvastatin (80 mg/day) was prescribed to
patients for two weeks prior to surgery. Paired paraffin embedded pre- and post-statin treatment tumor samples were
analyzed using immunohistochemistry for the expression of estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor 2 (HER2), and the cell cycle regulators cyclin D1 and p27. Corresponding frozen tumor
sample pairs were analyzed for expression of the genes coding for cyclin D1 and p27, CCND1 and CDKN1B, respectively.
Results: Forty-two patients completed all study parts, and immunohistochemical evaluation of ER and PR was achievable
in 30 tumor pairs, HER2 in 29 tumor pairs, cyclin D1 in 30 tumor pairs and p27 in 33 tumor pairs. The expression of ER, PR
and HER2 did not change significantly following atorvastatin treatment. Cyclin D1 expression in terms of nuclear intensity
was significantly decreased (P = 0.008) after statin treatment in paired tumor samples. The protein expression of the tumor
suppressor p27, evaluated either as the fraction of stained tumor cells or as cytoplasmic intensity, increased significantly
(P = 0.03 and P = 0.02, respectively). At the transcriptional level, no significant differences in mRNA expression were
detected for cyclin D1 (CCND1) and p27 (CDKN1B). However, CCND1 expression was lower in tumors responding to
atorvastatin treatment with a decrease in proliferation although not significantly (P = 0.08).
Conclusions: We have previously reported statin-induced anti-proliferative effects in breast cancer. This study suggests
that cell cycle regulatory effects may contribute to these anti-proliferative effects via cyclin D1 and p27.
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Statins, a major class of drugs for treatment of hypercholes-
terolemia, are widely used due to a notable prevention of
cardiovascular disease, and accumulating evidence proposes
a promising role of statins in breast cancer [1]. Statins act
by inhibiting 3-hydroxy-3methylglutaryl coenzyme-A re-
ductase (HMGCR), the rate-limiting enzyme of the* Correspondence: signe.borgquist@med.lu.se
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unless otherwise stated.mevalonate pathway, thereby reducing intracellular choles-
terol production [2]. In addition to their lipid-lowering
capacity, statins exert several other effects mediated by
different products of the mevalonate pathway. These lipid-
independent effects include inhibition of inflammatory
responses, immunomodulatory actions, apoptotic and anti-
proliferative effects, which might contribute to the sug-
gested anti-tumoral effects of these agents [3,4]. The
epidemiological evidence projecting statins as anticancer
agents is variable, depending on the particular type of can-
cer in question as well as the class of statin used [5-9].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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over hydrophilic statins as anticancer agents [10,11]. In
breast cancer, previous studies have shown lipophilic statin
use following a breast cancer diagnosis to be associated
with a decreased risk of disease recurrence and with re-
duced breast-cancer mortality [8,12,13]. Results from a
phase II study with statins prescribed in the pre-surgical
setting have demonstrated reduced tumor cell proliferation
and increased apoptosis in patients with high grade in situ
breast cancer [14]. The anti-proliferative effects of statins
were confirmed in invasive breast cancer, as reported in a
previous publication from the same trial on which this
study is based [15]. In both studies, the anti-proliferative ef-
fects were described in terms of decreased intra-tumoral
levels of Ki67 [14,15]. However, the comprehensive bio-
logical mechanisms behind this anti-proliferative effect are
currently not clear. Ki67 is the most widely used clinical
biomarker for assessing the proliferative status of a breast
cancer. Ki67 is expressed during all active phases of the cell
cycle (G1, S, G2, M), but is absent in resting cells (G0)
[16,17]. The cell cycle is a complex and strictly controlled
series of events, driving cell division and replication of
DNA. In normal cells, progression through the cell cycle is
controlled by the cyclin dependent kinases (CDKs), a family
of serine/threonine kinases [18]. The CDKs form com-
plexes with their regulatory units, cyclins, thereby activating
the CDKs, leading to phosphorylation of the cell cycle regu-
latory proteins that initiate and regulate progression
through the different phases of the cell cycle [19]. In breast
cancer cells, the cell cycle control system is deregulated at
multiple levels, leading to abnormal cell proliferation [20].
Cyclin D1 is a vital regulator of the G1/S transition, as il-
lustrated in Figure 1. The interaction of cyclin D1 with
CDK4 and CDK6, leads to phosphorylation and thereby in-
activation of the Rb-protein and its G1-maintaining func-
tion, which culminates in the expression of proliferation-
associated target genes [21,22]. Cyclin D1 is overexpressed
at the protein level in up to 50% of all primary breast can-
cers, in part due to amplification of the cyclin D1 gene,
CCND1 [23]. The CDK inhibitor p27, also known as Kip1,
is involved in the regulation of the G0-to-S-phase transi-
tion. p27 interacts with CDK2-cyclin E, CDK4/6-cyclin D,
and CDK2-cyclin A complexes, thereby regulating these
complexes strictly [24,25]. The tumor suppressor p27 is
frequently deregulated in breast cancer, and reduced p27
expression has been associated with increased prolifera-
tion, high tumor grade, HER2 amplification as well as es-
trogen receptor (ER) and progesterone receptor (PR)
negativity [25,26].
The aim of this study was to investigate potential
statin-induced effects on the central cell cycle regulators
cyclin D1 and p27, to improve the understanding of the
statin induced anti-proliferative effects previously re-
ported. A secondary aim was to evaluate the expressionof clinically established biomarkers, such as the estrogen
receptor, progesterone receptor and HER2 before and
after atorvastatin treatment, hypothesizing no statin-
induced changes of their expression. These aims were
addressed in a phase II window-of-opportunity trial with
two-week, pre-operative high-dose atorvastatin therapy
in 50 patients with primary invasive breast cancer.
Materials and methods
Trial design
The trial was designed as a window-of-opportunity study,
in which the participants were prescribed the lipophilic
statin atorvastatin for two weeks, during the treatment-
free window between breast cancer diagnosis and surgery.
The study was opened for recruitment in February 2009,
and the pre-planned number of 50 patients was achieved
in March 2012. In this non-randomized phase II trial, all
patients received an equal dose of 80 mg atorvastatin
daily. The trial was conducted as a single center study at
Skåne University Hospital in Lund, Sweden.
The Ethical Committee at Lund University and the
Swedish Medical Products Agency approved this trial.
The study has been registered at ClinicalTrials.gov (i.e.,
ID number: NCT00816244, NIH). The study adheres to
the REMARK criteria [27].
Patients and tumors
Patients diagnosed with primary invasive breast cancer
with a minimum tumor size of 15 mm measured by
ultrasound, who were candidates for radical surgery,
were eligible for participation in this study. A perform-
ance status below 2 according to the European Coopera-
tive Oncology Group (ECOG) and normal liver function
were also required for inclusion. Pregnancy, on-going
hormonal replacement therapy, cholesterol lowering
therapy (i.e., including statins, fibrates, and ezetemibe), a
medical history of hemorrhagic stroke or allergic reac-
tions attributed to compounds with a similar biological
composition to that of atorvastatin encompassed the ex-
clusion criteria. Complete information regarding the
study inclusion and exclusion criteria, as well as clinical
and pathological characteristics of the patients and tu-
mors have been described in detail previously [15].
Following inclusion, the participants underwent study
specific tumor core biopsies prior to statin treatment ini-
tiation with one core biopsy being formalin-fixed imme-
diately and one being fresh frozen at −80°C. Subsequent
to the two-weeks statin treatment, breast surgery was
performed according to standard surgical procedures,
and tumor tissue was retrieved from the primary tumor
at the Department of Pathology at Skåne University
Hospital, Lund, Sweden. Of the 50 patients enrolled in
the study, a total of 42 patients completed all study
parts. Two patients were excluded from the trial since
Figure 1 The cell cycle, and the main actions of cyclin D1 and p27. Cyclin D1 regulates the G1/S-phase transition, binds and activates Cdk4/Cdk6 to
phosphorylate the retinoblastoma (pRb) protein. Phosphorylation of Rb leads to separation from E2F, and allows the transcription of proliferation genes
[21]. In G0 and early G1, p27 inhibits CDK2-cyclin E, and in S-phase CDK2-cyclin A. In G1 there is a decrease in p27, allowing CDK2-cyclin E and CDK2-cyclin
A to activate the transcription of genes acquired for the G1-S-transition [25]. P27 also interacts with CDK4/6-cyclin D comprehensively, p27 acting as both
an inhibitor and as a required assembly factor for the complex, depending on the growth state of the cell [24].
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patients were excluded due to elevated serum levels of
alanine aminotransferase. One patient was excluded
since the diagnose of invasive breast cancer was ques-
tioned, one patient left the study due to nausea and diz-
ziness and two patients left due to personal reasons.Endpoints and tumor evaluation
The primary endpoint of the clinical trial was statin-
induced anti-proliferative tumor response measured by a
decrease in Ki67 expression, as previously reported [15].
The purpose of this sub-study was to investigate poten-
tial effects of statin treatment on the expression of ER,
PR, and HER2 as well as the expression of the cell cycle
regulators cyclin D1 and p27.Immunohistochemistry
Formalin-fixed and paraffin-embedded tumor tissue from
core biopsies and surgical samples were cut into 3 to 4 μm
sections and transferred to glass slides (Menzel Super Frost
Plus), dried at room temperature, and baked in a heated
chamber for 2 hours at 60○C. De-paraffinization and anti-
gen retrieval was performed using PT Link (Dako
Denmark A/S) using a high pH buffer. Staining was per-
formed in an Autostainer Plus (Dako) using a di-amino-
benzidine (DAB) based visualization kit (K801021-2,
Dako). Counterstaining was performed using Mayer’s
hematoxylin with antibodies against ER (SP1, Thermo
Scientific, diluted 1:200), PR (Dako M3569, diluted 1:200),
HER2 (4B5, Ventan BenchMark Ultra, Ventana Medical
Systems, Inc. Tucson, Arizona, R.U.), cyclin D1 (Dako
M3635, diluted 1:40), and p27 (Dako M7203, diluted 1:100).
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ER and PR expression was evaluated as the fraction of
stained nuclei, using a five-grade scale (i.e. 0-1%, 2-10%,
11-50%, 51-75% and >75% of stained cells). HER2 was
evaluated using the HercepTest guidelines (DAKO,
Carpinteria, CA) for scoring of HER2. No staining ob-
served in <10% of the tumor cells was scored 0, faint
staining observed in >10% of the tumor cells was scored
1+, weak to moderate staining in >10% of the tumor
cells was scored 2+, and strong staining in >10% of the
tumor cells was scored 3+, according to the guidelines.
Assessment of cyclin D1 and p27 protein expression was
evaluated by considering the fraction of stained nuclei,
using a five-grade scale (i.e. 0-1%, 2-10%, 11-50%, 51-
75% and >75% of stained cells), and nuclear intensity
and cytoplasmic intensity, using a four-grade scale (i.e.
negative, weak, moderate or strong) (Additional file 1:
Figure S1 and Additional file 2: Figure S2). For Ki67 as-
sessment, 400 tumor cells were evaluated and Ki67 ex-
pression recorded as the fraction of positive nuclei using
a continuous scale from 0 to 100 [15].
RNA extraction
Total RNA was extracted from fresh frozen tumor sam-
ples using the Allprep DNA/RNA mini kit (QIAGEN,
Valencia, CA) in a QIAcube (Qiagen) according to the
manufacturer's instructions. The RNA integrity was
assessed on an Agilent 2100 Bioanalyzer (Agilent, Santa
Clara, CA) and RNA quantification was performed using a
NanoDrop ND-1000 (NanoDrop Products, Wilmington,
DE). The samples were hybridized to Human HT-12 v4.0
Expression BeadChips (Illumina Inc, San Diego, CA) in
two batches at the SCIBLU Genomics Center at Lund
University, Sweden (www.lth.se/sciblu). The Illumina
probes were re-annotated using the R package illumina-
Humanv4.db [28]. The microarray study was conducted
within another sub-study of the trial and comprehensive
analyses of the data are subject of currently unpublished
work. Thus, in this study only analyses concerning the ex-
pression of the probes representing cyclin D1 and p27 are
reported herein.
Statistical analysis
All assessed immunohistochemical tumor variables were
measured on ordinal scales. Changes in ER, PR, HER2,
cyclin D1 and p27 protein expression between pre- and
post-atorvastatin treatment samples were evaluated
using the Wilcoxon matched-pairs signed-rank test.
Spearman’s rho was used as a measure of the correlation
between change in cyclin D1 and Ki67, and p27 and Ki67,
respectively. To test for subgroup differences, the Linear-
by-linear association was used. All tests were two-sided and
differences with P-values below 5% were considered signifi-
cant. The software packages Stata version 12.1 (StataCorpLP, College Station, TX, 2012) and IBM SPSS Statistics Ver-
sion 19, were used for the data analysis.
For microarray data analysis, all data were initially
pre-processed and normalized using the Quantile
Normalization method [29]. The GenomeStudio Soft-
ware V2011.1 was used for the analyses. Probe sets with
signal intensity below the median intensity of negative
control signals in 80% of the samples were excluded.
Replicate probe sets were merged by the median of sig-
nal intensity values. A Significance Analysis of Microar-
rays (SAM) analysis was performed using the TMeV
v4.9 software to identify differences in expression of
CCND1 and CDKN1B between paired pre- and post-
statin treatment samples. Furthermore, changes in the
expression of CCND1 and CDKN1B between tumor
pairs stratified into two groups according to statin-
induced changes in Ki67 expression were evaluated
using the Mann–Whitney U-test. Changes in tumor
proliferative rate, quantified by IHC analysis of the ex-
pression of Ki67, have been previously reported [15].
Results
Patient characteristics and tumor data
Fifty patients entered the trial; a total of 41 patients were
reported as postmenopausal and nine patients as pre-
menopausal. Forty-two patients completed all study
parts. No serious adverse events were reported. At the
time of diagnosis, the average age among all 42 patients
was 63 years (range 35–89 years). The average patho-
logical tumor size was 21 mm, ranging from 6 to 33 mm
and all 42 tumors were invasive breast cancers. Most tu-
mors were ductal cancers, and the majority of tumors
were histological grade 2 or 3 (Table 1).
Changes in the expression of ER, PR, HER2
The evaluation of ER and PR was achievable in 30 tumor
pairs and HER2 in 29 pairs, respectively, whereas the
remaining pre-treatment biopsies showed insufficient
amount of tumor tissue for immunohistochemical evalu-
ation of these markers. The baseline expression of ER, PR
and HER2 is shown in Table 1. When contrasting the pre-
and post-treatment samples, neither ER, PR nor HER2
changed significantly (Wilcoxon matched-pairs signed-
rank test P = 0.68, P = 0.19, and P = 0.08 for ER, PR and
HER respectively; Table 2) and the null hypothesis of equal
expression before and after statin treatment was retained.
Changes in the expression of cyclin D1
Immunohistochemical evaluation of cyclin D1 was
achievable in 30 of the 42 paired samples restricted by
insufficient amount of tumor tissue in the remaining
core biopsies. Table 3 shows cyclin D1 expression in the
pre-treatment samples. A comparison of the expression
of cyclin D1 between pre-and post-treatment samples is
Table 1 Patient- and tumor characteristics
Patients completed all study parts n = 42
Age years (mean, range) 63 (35–89)
Tumor size mm (mean, range) 21 (6–33)









ER (n = 30)
Positive 27 (90%)
Negative 3 (10%)
PR (n = 30)
Positive 24(80%)
Negative 6 (20%)





Ki67 index (n = 26)
Low 15 (58%)
High 11 (42%)
HMGCR (n = 38)
Positive 24 (63%)
Negative 14 (37%)
NHG Nottingham histologic grade I-III (post-treatment pathological report),
Mitotic index according to Nottingham criteria (post-treatment
pathological report).
Baseline tumor data (pre-treatment): ER (estrogen receptor), PR (progesterone
receptor), HER2 (human epidermal growth factor receptor 2), Ki67 high if >20%,
HMGCR positive if any cytoplasmic staining.
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expressed cyclin D1. However, the nuclear intensity of
the protein expression was significantly decreased (P =
0.008, Wilcoxon matched-pairs signed-rank test) follow-
ing statin treatment (Table 2). Furthermore, cyclin D1
expression was assessed regarding the fraction of stained
nuclei as well as the intensity of cytoplasmic staining,
but neither the nuclear fraction nor the cytoplasmic
intensity changed significantly following treatment. No
significant association was found between the pre-
treatment tumor characteristics in relation to the change
in cyclin D1 following atorvastatin treatment (Additional
file 3: Table S1).Changes in the expression of p27
Immunohistochemical evaluation of p27 could be per-
formed for 33 of the 42 paired tumor samples. Prior to
atorvastatin treatment, all samples demonstrated tumor
cells expressing p27 to a different extent as shown in
Table 3. Following atorvastatin treatment there was a
significant increase in the fraction of tumor cells ex-
pressing p27 (P = 0.03, Wilcoxon matched-pairs signed-
rank test, Table 2 and Figure 3). The nuclear intensity of
p27 did not change significantly (P = 0.35). Further, the
cytoplasmic intensity of p27 was significantly increased
after atorvastatin treatment (P = 0.02, Wilcoxon matched-
pairs signed-rank test). Baseline tumor characteristics in
relation to the change in p27 expression following atorva-
statin treatment are summarized in Additional file 4: Table
S2, for which no significant associations were found.
Correlation between change in Ki67 and change in cyclin
D1 or p27
Spearman´s correlation was used to evaluate whether a
change in the expression of cyclin D1 or p27 was accom-
panied by a change in proliferation as determined by Ki67.
We observed that a decrease in Ki67 corresponded posi-
tively with a decrease in cytoplasmic intensity of cyclin D1
(N = 25, P = 0.03, Spearman’s rho = 0.43), as illustrated in
Figure 4. No significant associations were detected be-
tween the decrease in Ki67 and the change in nuclear frac-
tion or nuclear intensity of cyclin D1, or the change in
Ki67 and the change in p27 irrespective of cellular
localization or staining intensity.
mRNA expression of proliferation associated genes
Initially, we compared the expression of CCND1 and
CDKN1B between paired pre-and post-treatment samples.
Good quality gene expression data were available for
twenty-five tumor pairs; no statistically significant differ-
ence in the expression of these genes was noted. Next, a
sub-analysis comparing the mRNA levels of CCND1 and
CDKN1B was performed after dividing samples into two
groups based on changes in Ki67 expression as assessed by
IHC. Ki67 expression was decreased in 15 samples while 10
samples showed an increased expression as previously re-
ported [15]. Separate analyses were performed for the pre-
and post-treatment samples. As illustrated in Figure 5A,
the expression of CCND1 in the pre-treatment samples
was significantly correlated to response in tumor cell prolif-
eration (P = 0.02; Mann–Whitney). Correspondingly, in the
post-treatment samples, a marginally lower CCND1 expres-
sion was observed among the tumors responding with a de-
crease in Ki67 compared to tumors with an increase in
Ki67 (Figure 5B; P = 0.08; Mann–Whitney). CDKN1B
mRNA expression did not differ significantly between
tumors responding with a Ki67 response or not (Figure 5C-
D; P = 0.3, 0.06: Mann–Whitney).
Table 3 Cyclin D1 and p27 tumor expression in the
pre-treatment setting
Patients completed all study parts n = 42
Cyclin D1 nuclear fraction (n = 30)
Negative 2 (7%)
Low (1-50%) 12 (40%)
High (51-100%) 16 (53%)










p27 nuclear fraction (n = 33)
Negative 0
Low (1-50%) 8 (24%)
High (51-100%) 25 (76%)










Table 2 Change in tumor expression from baseline (i.e. before atorvastatin treatment) to time of surgery (i.e. after
atorvastatin treatment)
Complete pairs Decreasing Unaltered Increasing P-value
ER n = 30 2 25 3 0.68
PR n = 30 3 21 6 0.19
HER2 n = 29 7 20 2 0.08
Cyclin D1 nuclear fraction n = 30 4 19 7 0.12
Cyclin D1 nuclear intensity n = 30 14 13 3 0.008*
Cyclin D1 cytoplasmic intensity n = 30 10 14 6 0.48
p27 nuclear fraction n = 33 2 22 9 0.03
p27 nuclear intensity n = 33 9 18 6 0.35
p27 cytoplasmic intensity n = 33 3 18 12 0.02
P-values from Wilcoxon matched-pairs signed-ranks test.
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
*Significant even after Bonferroni adjustment for multiple testing within the marker, P = 0.02.
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In the present study, we investigated the effects of short-
term administration of a high-dose of atorvastatin on
the conventional breast cancer pathological markers ER,
PR, HER2, as well as the cell cycle regulators cyclin D1
and p27. Our results indicate that ER, PR and HER2 ex-
pression remain stable following treatment with atorva-
statin. However, a significant decrease in cyclin D1
expression and a significant increase in p27 expression
were observed, indicating that the anti-proliferative ef-
fects of statins may be driven by the cell cycle regulatory
effects of cyclin D1 and p27.
There is a rising interest in statins, due to their effects
extending beyond their well-known lipid-lowering cap-
acity [3]. As previously reported from this trial, a signifi-
cant decrease in tumor proliferation, in terms of decrease
in Ki67 expression, was noted especially in the sub-set of
tumors expressing HMGCR at baseline [15]. This differ-
ence in proliferation may be driven by changes in the cell
cycle regulators cyclin D1 and p27, as has been addressed
in this study. It has been proposed that the anti-
proliferative and pro-apoptotic effects of statins are due
to the inhibition of downstream isoprenoid intermediates,
such as farnesyl-pyrophosphate (FPP) and geranyl-
geranyl-pyrophosphate (GGPP) [30-32]. FPP and GGPP
are molecules which post-translationally modify a number
of proteins by creating a hydrophobic domain, thereby
allowing the proteins to anchor to cell membranes and
perform their normal functions, a process known as pro-
tein prenylation [33]. Protein prenylation is necessary for
the activation of many proteins participating in signaling
pathways on which tumors depend, such as the RAS/Rho
superfamily. RAS-dependent pathways regulate the ex-
pression of both p27 and cyclin D1, the assembly of cyclin
D1 with CDK4/6, and the growth factor-induced regula-



























Figure 2 Change in tumor expression of cyclin D1 from baseline (i.e., before atorvastatin treatment) to time of surgery (i.e., after atorvastatin
treatment). A) Fraction of stained nuclei; B) Nuclear intensity; C) Cytoplasmic intensity. To reduce the problem of completely overlapping lines in
the spaghetti plot, for each pair of pre/post-treatment samples, a random number from a uniform distribution over the interval [−0.15, 0.15] was
added, shifting the corresponding line at most 15%, upwards or downwards, of a step on the integer-valued score scale.
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shown to inhibit cell growth, with G1 arrest, leading to re-
duced transition to the S and G2/M phases of the cell
cycle [35]. Both cyclin D1 and p27 are involved in the
regulation of these transitions, cyclin D1 through the asso-


















Figure 3 Change in tumor expression of p27 from baseline (i.e., before atorva
A) Fraction of stained nuclei; B) Nuclear intensity; C) Cytoplasmic intensity. To
plot, for each pair of pre/post-treatment samples, a random number from a u
corresponding line at most 15%, upwards or downwards, of a step on the intthe CDK2/cyclin E, CDK2/cyclin A, and CDK4/6-cyclin D
complexes. A decrease in cyclin D1 entails that p27 is re-
leased from the CDK4/6-cyclin D complex, and instead
able to assemble with, and inhibit CDK2, thereby promot-
ing cell cycle arrest and inhibit proliferation [24]. This sug-












statin treatment) to time of surgery (i.e., after atorvastatin treatment).
reduce the problem of completely overlapping lines in the spaghetti
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Figure 4 Correlation between change in Ki67 and change in cyclin D1 (cytoplasmic intensity) after treatment with atorvastatin. Marker color and filling
represents immunohistochemical scoring of cyclin D1 cytoplasmic intensity in the pre-treatment samples; filled red circles (strong cyclin D1 intensity),
red empty circles (moderate cyclin D1 internsity), green empty circles (week cyclin D1 intensity), green filled circles (no cyclin D1 expression).
Pre-treatment gene expression Post-treatment gene expression
Mann-Whitney P=0.08Mann-Whitney P=0.02
Mann-Whitney P=0.3 Mann-Whitney P=0.06
A) B)
C) D)
Figure 5 Expression of CCND1 and CDKN1B pre- and post-atorvastatin treatment, divided into tumors responding with a decrease or increase in
proliferation (Ki67) following statin treatment. A) Pre-treatment CCND1 expression, B) Post-treatment CCND1 expression, C) Pre-treatment CDKN1B
expression, D) Post-treatment CDKN1B expression.
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corresponding increase in p27 as suggested by our data.
Previous in vitro studies have shown similar results with a
statin induced up-regulation of p27 [36-38] and reduced
levels of cyclin D1 [39] in various tumor cell lines. Cyclin
D1 and p27 are both regulated by a plethora of different
signal transduction pathways [25,40], and the under-
lying mechanisms of the observed decrease of cyclin D1
and increase of p27 in this study is not evident. Given
the suggested effects of statins on cell cycle regulators
and the recent approval of a CDK4/6-inhibitor for first-
line treatment of advanced ER positive breast cancer
[41], further studies examining the potential synergistic
effects of statins and CDK4/6 inhibitors would be of
clinical importance.
The expression of clinically established biomarkers
such as ER, PR and HER2 was evaluated in both pre-and
post-treatment samples to establish whether these markers
were affected by statin treatment. The vast majority of
samples pairs remained unchanged. Recently, the choles-
terol metabolite 27-hydroxycholesterol (27HC), has been
revealed to increase ER-dependent growth in mouse
models of breast cancer [42]. In the endocrinological field
of research, 27HC has been linked to a decrease in bone
mineral density, in part due to its ability to bind to and
modulate the transcriptional activity of ER [43]. An
in vitro study showed that simvastatin exerted osteoinduc-
tive effects, partly achieved through an increase in ER ex-
pression [44]. Regarding HER2, signaling through this
receptor is dependent on the cholesterol content of the
lipid rafts [45]. Thus, statins may theoretically enable
changes in the expression of both steroid receptors and
HER2. Such changes were not detected in this study.
However, the treatment duration of only two weeks might
be insufficient to índuce changes in ER or PR expression,
due to their relatively stable nature [46,47]. The absence of
a significant change in the expression of ER, PR and HER2
might be of clinical interest, indicating that statin treat-
ment can be administrated safely to breast cancer patients
without altering clinically used prognostic and treatment
predictive markers. In the immunohistochemical evalua-
tions of cyclin D1 and p27, expression was scored for both
percentage of positive nuclei, nuclear intensity and cyto-
plasmic intensity. Currently, established scoring systems
for immunohistochemical evaluation of cyclin D1 and p27
are not available. In a review by Chu et al., [25] most prog-
nostic studies scored p27 based on the percentage of posi-
tive tumor nuclei, with various cut-offs. Others scored
both the percentage of positive nuclei and the intensity of
the staining. Most studies however omitted scoring of
cytoplasmic expression of p27. In this study, immunohis-
tochemical evaluations demonstrated significant changes
regarding the cyclin D1 nuclear intensity, fraction of p27
stained cells, and the cytoplasmic intensity of p27. Bothcyclin D1 and p27 exert their effects on the G1/S transi-
tion control when localized to the nucleus [25,48] A de-
crease of cyclin D1, results in p27 no longer being
sequestrated by the CDK4/6-cyclin D complex to the
same extent. Data suggest that the cell favours maintai-
nance of low levels of p27 in the nuclear space, and subse-
quently mislocalize p27 to the cytoplasmic compartment
when levels of nuclear p27 are increased [24], which may
explain the concurrent increase in expression of p27 in
both the nuclear and cytoplasmic compartments in this
study. Importantly, data from functional studies suggest
that cytoplasmic translocation of p27 can change its func-
tion in tumor cells [49], thus promoting other functions
opposite to its tumor suppressor role, e.g. cell migration
[50]. A review by Guan et al. concluded that further stud-
ies were needed to understand the role of cytoplasmic p27
in breast cancer [26]. However, the significance of the cel-
lular localization of p27 cannot be explained based on the
results from this study. The cytoplasmic intensity of cyclin
D1 was associated with Ki67 (Figure 4), although expres-
sion did not change significantly during treatment. During
G1, cyclin D1 accumulates in the nucleus, but is exported
to the cytoplasmic space when the cell enters S-phase
[48], possibly implying a more intense cytoplasmic cyclin
D1 staining in high proliferating aggressive tumors, a cor-
relation found in pancreatic adenocarcinoma [51], and
suggestively explaining the positive correlation with Ki67.
Further, gene expression analyses of paired tumor samples
were performed. Only marginal changes in CCDN1 and
CDKN1B expression were observed following two weeks
of statin treatment. However, the cell cycle-dependent
changes in cyclin D1 and p27 can both ensue through
other mechanisms, including post transcriptional deregula-
tion. [23,25]. The gene expression of CCND1 was found to
be significantly correlated to response in tumor cell prolif-
eration, indicating a difference in the response to statins
between cancers with or without CCND1 overexpression.
Whether and how the dose or duration of statin treat-
ment influences the here presented results is unclear
and cannot be further elucidated from this trial, as all
patients in the study were given atorvastatin for two
weeks at the maximum recommended dose to optimize
the drug delivery into the breast cancer cells. No serious
adverse events were observed, and only one patient
withdrew from the study due to side effects, indicating
that the treatment with high-dose atorvastatin was well-
tolerated during the two-week administration. To gain
more insight regarding the statin-induced effects on ex-
pression of cell cycle regulators, prolonged treatment
duration may be neccessary to demonstrate the maximal
effect on cell cycle regulators. However, due to ethical
considerations, this window-study was not able to ex-
tend the time from diagnosis to surgery, which restricted
the duration of statin treatment to two weeks. Thus, as
Feldt et al. Journal of Translational Medicine  (2015) 13:133 Page 10 of 11implied in the trial design and purpose of window-trials,
these trials can generate adequate hypotheses which
should preferably be evaluated in larger phase III trials
[52]. As recently proposed by Ahern et al., the existing
evidence supporting a protective effect of statins on
breast cancer prognosis, is considered sufficient to
launch a clinical phase III trial with statins in the adju-
vant setting [1].
Conclusions
In conclusion, the results from this window-of-opportunity
study indicate a statin induced effect on central cell cycle
regulators, in terms of an up-regulated expression of the
tumor suppressor p27 and down-regulated expression of
the oncogene cyclin D1 in breast cancer. The results are
concordant with previous trial results, and suggest that cell
cycle regulatory effects may be contributing to the anti-
proliferative effects via cyclin D1 and p27.
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